First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.

Abstract

BACKGROUND:

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder causing multiple hamartomas. Treatment of TSC lesions with mammalian target of rapamycin inhibitors is effective. Recently, several reports have shown the efficacy of topical rapamycin (sirolimus) for angiofibromas. However, almost all studies have been case studies and the 0·1% solution caused skin irritation. A comparative study of topical rapamycin and a vehicle has not yet been reported.

OBJECTIVES:

To compare the efficacy of topical rapamycin formulation with that of vehicle for angiofibromas.

METHODS:

A left-right comparative study between rapamycin 0·2% topical formulation and vehicle was conducted in 11 patients with TSC. Two formulations, an ointment and a gel, were prepared and in vitro percutaneous absorption of rapamycin was determined.

RESULTS:

In vitro percutaneous absorption of rapamycin was significantly greater with the gel compared with the ointment. In the clinical study, the rapamycin-treated cheek showed significant improvements relative to the vehicle-treated cheek in all outcome measures after 12 weeks of treatment. The improvement was particularly remarkable in children aged ≤ 10 years. No side-effects were noted, and rapamycin was not detected in the blood of the patients.

CONCLUSIONS:

Topical rapamycin was significantly effective against angiofibromas. Both formulations used were effective and safe. The 0·2% gel is especially useful because of its better skin penetration and low irritancy. Initiation of topical rapamycin therapy in early childhood would be beneficial for patients with TSC.

• Authors: M Tanaka, M Wataya-Kaneda, A Nakamura, S Matsumoto, I Katayama
• Journal: The British journal of dermatology (Br J Dermatol) Vol. 169 Issue 6 Pg. 1314-8 (Dec 2013) ISSN: 1365-2133 [Electronic] England
• PMID: 23909960 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2013 British Association of Dermatologists.

Chemical References

• Antibiotics, Antineoplastic
• Gels
• Ointments
• Sirolimus

Topics

• Administration, Cutaneous
• Adolescent
• Adult
• Angiofibroma (complications, drug therapy)
• Antibiotics, Antineoplastic (administration & dosage)
• Child
• Child, Preschool
• Facial Neoplasms (complications, drug therapy)
• Female
• Gels (administration & dosage)
• Humans
• Male
• Neoplasm Recurrence, Local (etiology)
• Ointments (administration & dosage)
• Sirolimus (administration & dosage)
• Treatment Outcome
• Tuberous Sclerosis (complications)